Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
STAT+
First Opinion
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Wall Street reacts to Regeneron, Sanofi cholesterol drug study results

  • Adam Feuerstein
  • Damian Garde

By Adam Feuerstein and Damian Garde March 12, 2018

Reprints
Clogged Artery
APStock

Updated with stock prices.

It’s Monday, which means Wall Street is having a say about the results from a long-anticipated clinical trial of the cholesterol-lowering drug Praluent that were presented Saturday by Regeneron Pharmaceuticals and Sanofi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Damian Garde

Damian Garde

National Biotech Reporter

Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

As billionaires race to fund anti-aging projects, a much-discussed…
As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Amid Aduhelm woes, Biogen moves to pare back office…
Amid Aduhelm woes, Biogen moves to pare back office space
Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent;…
Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent; U.S. to allow fractional doses of monkeypox…
Everything you need to know before the next big…
Everything you need to know before the next big Alzheimer’s readout

Comments are closed.

Recommended Stories